Clinical Trial Update: SGLT2 Inhibition in Hemodialysis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating SGLT2 inhibitors in patients undergoing hemodialysis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease
• Left Ventricular Hypertrophy
• Type 2 Diabetes Mellitus

Drugs mentioned

• SGLT2 inhibitor (class) (SGLT2 inhibitor)

Snippet

Sponsor: Medical University of Vienna | Conditions: Kidney Failure, Hemodialysis | Phase 2 | Status: COMPLETED